Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569672 · ClinicalTrials.gov registry record · NA
Ohio Patient Navigator Research Program
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 941
- Enrollment target
NCT01569672: Completed NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01569672 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 941 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01569672, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 941 participants
- Enrollment target
Study Summary
The Ohio Patient Navigator Research Program (OPNRP) proposes to alleviate disparities in relation to the timely diagnosis and treatment of breast, cervical and colorectal cancer in Columbus, OH.
Primary Outcome
How much time exist between an abnormal test diagnosis for breast, cervical or colon or rectum cancer to when the needed follow up tests or treatment is done.
Interventions
- BEHAVIORAL Patient Navigator matched with subject
- BEHAVIORAL Subjects are mailed informational/educational materials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2006-11 |
| Est. Completion | 2020-12-31 |
| Phase | NA |
What the finished NCT01569672 record still lists
NCT01569672 is an interventional study that assigns participants to a tested intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Patient Navigator matched with subject is the first listed.
NCT01569672 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01569672 about?
NCT01569672 is a clinical study titled "Ohio Patient Navigator Research Program". The Ohio Patient Navigator Research Program (OPNRP) proposes to alleviate disparities in relation to the timely diagnosis and treatment of breast, cervical and colorectal cancer in Columbus, OH.
What is the current status of trial NCT01569672?
This trial is currently completed. It is a NA study. The enrollment target is 941 participants. The study started on 2006-11. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT01569672?
The interventions under investigation include: Patient Navigator matched with subject (BEHAVIORAL), Subjects are mailed informational/educational materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT01569672?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01569672's enrollment target sits among peer trials
941 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia